For Immediate Release: Pfizer may pay YOU $35 for every AFLB share you own?

By Announcing The Greatest Medical Breakthrough Of The 21st Century, This $.73 Powerhouse Could Return Investors A 4694% Profit By November 1, 2010 I'll prove below, why a buyout by Merck, Pfizer or Johnson & Johnson may be virtually guaranteed as your $.73 shares soar to $35 or higher! Future Millionaire, I'm about to show you what may very well be the greatest medical breakthrough since Penicillin... My #1 bio-tech pick of 2010, A5 Laboratories (AFLB), has just unveiled a new way to produce one of today's most important ingredients in drug therapy - interferon - setting themselves up as a strong buyout target by a major pharmaceutical company, like Roche or Johnson & Johnson. I'm going to literally prove to you why a buyout of AFLB at $35 a share could be right around the corner. But before we get into the big buyout possiblities, let me tell you about their earthshattering new discovery... What are interferons - and why are they so important? Besides being the keys to unlocking your door to untold wealth... Interferons are naturally-occuring proteins made by white blood cells. They perform many critical immune functions like fighting disease and even cancer cells! Too few interferons in your body, and death could be knocking at your door. This is why they're used by many of today's biggest pharmaceutical companies in dozens of blockbuster drugs. This is a booming $9 billion annual business. You see, the interferon Big Pharma is using now is expensive, often toxic and hard to make. Quite frankly, it's junk compared to what I'm about to reveal, but quite honestly, they haven't had any other options... until now! As we speak, A5 Labortories (AFLB) are creating an inexpensive, non-toxic and completely natural interferon that could turn the entire medical world on it's head, and by doing so, capturing 100% of the interferon market... Yes, you read that correctly - 100%! But best of all, (especially for early investors) A5 Laboratories (AFLB) is planning on selling their propreitary interferon to Big Pharma for just 1/7th the price, which could potentially mean profit margins in excess of 93%! "And here's the kicker! A5 Laboratories (AFLB) could easily capture a huge chunk of this $9 billion and growing market." This isn't science fiction, it's science FACT! Interferon is a proven medical commodity that's already approved and used in hundreds of drugs, many of them with annual sales in the $billions. Remember, A5 Laboratories' interferon (for which they have 3 patents pending and world-wide manufacturing rights)is 100% natural. This company could very well revolutionize medical treatment as we know it, for both humans and animals. And I don't have to tell what that'll mean to early share-holders who accumulate AFLB shares between $.75 and $1.50 right now... Why I see a fast and high-priced buyout of AFLB on the horizon The fastest way for AFLB to become a Billion dollar company (and generate gargantuan profits for early A5 investors) is obvioulsy the big money buyout, which I'm about to prove, is almost a certainty. But there's another way... A5 may very well cut a licensing deal with Big Pharma names like Pfizer and Roche, to make and add A5's interferon to their already successful drugs. Assuming A5's interferon makes these drugs far more effective, sales could easily double, as it becomes the drug of choice. Then, A5 will collect a percentage-of-sales royalty on the new formulation. And if Pfizer and Roche don't want in, I'm sure Biogen would love to add A5's interferon to its products, maybe quadrupling its current $1.7 billion annual sales to $6.8 Billion, while largely killing sales of those companies sitting on the sidelines. Do you see why my numero uno bio-tech pick of the year, A5 Laboratories, is almost guaranteed to lock in profits of 4694% for early investors? By clicking HERE you'll get the whole story on why A5 Laboratories could be... The Biggest Buyout Target of 2010!! Mark this date on your calender, AFLB could be on it's way to $Billion profits with two ways to win - a high-priced buyout or a profitable licensing agreement - with what could be the single greatest breakthrough in drug technology of our lifetime!! I urge you to read this special report before a buyout or licensing agreement is met, by then it'll be too late. Select here to read on...   Happy Investing, Tim Fields Untapped Wealth IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Untapped Wealth does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Untapped Wealth or an offer or solicitation to buy or sell any security. A5 Laboratories, (AFLB), the company featured in this issue, appears as paid advertising, paid by Towson Development Ltd. to provide public awareness for AFLB. Towson Development Ltd. has approved and signed off as approved for public dissemination all statements made herein regarding AFLB's history, assets, technologies, current as well as prospective business operations and industry information. Untapped Wealth and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Untapped Wealth about AFLB. Although the information contained in this advertisement is believed to be reliable, Untapped Wealth and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Untapped Wealth is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state se- curity administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $700,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Untapped Wealth is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from A5 Laboratories's investor relations firm, or at A5 Laboratories's website www.a5labs.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like A5 Laboratories, advice to in- vestors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after con- sulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, A5 Laboratories notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may af- fect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.